よむ、つかう、まなぶ。
会議資料 (162 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00044.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第66回 12／12）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
要望番号；IV-203
For the use of the WHO-recommended standardized shorter-course 9- to 12-month regimen
for MDR-TB:
20. The shorter-course regimen is standardized with the use of kanamycin (which the
committee recommends against using) and includes drugs for which there is
documented or high likelihood of resistance (e.g., isoniazid, ethionamide,
pyrazinamide). Although the STREAM (Standard Treatment Regimen of AntiTuberculosis Drugs for Patients with MDR-TB) Stage 1 randomized trial found the
shorter-course regimen to be noninferior to longer injectable-containing regimens with
108
162 / 451
For the use of the WHO-recommended standardized shorter-course 9- to 12-month regimen
for MDR-TB:
20. The shorter-course regimen is standardized with the use of kanamycin (which the
committee recommends against using) and includes drugs for which there is
documented or high likelihood of resistance (e.g., isoniazid, ethionamide,
pyrazinamide). Although the STREAM (Standard Treatment Regimen of AntiTuberculosis Drugs for Patients with MDR-TB) Stage 1 randomized trial found the
shorter-course regimen to be noninferior to longer injectable-containing regimens with
108
162 / 451